qPCR设备市场－全球产业规模、份额、趋势、机会、预测：按检测类型、地区和竞争格局划分，2021-2031年

全球 qPCR 设备市场预计将从 2025 年的 12.9 亿美元成长到 2031 年的 19.4 亿美元，复合年增长率为 7.04%。

该市场包含整合热循环和萤光检测技术的先进分析平台，透过即时扩增和定量核酸，在生命科学研究和临床诊断中发挥至关重要的作用。推动这一市场成长的关键因素是全球遗传性疾病和感染疾病需要高灵敏度和快速的分子检测能力。此外，对基因组研究的持续投入以及个人化医疗通讯协定的广泛应用，也为这些精准诊断工具的持续需求提供了重要的支撑，确保其在瞬息万变的技术浪潮中依然具有重要意义。

然而，体外诊断领域日益严格的法规环境为市场带来了重大障碍。这给设备製造商带来了沉重的合规责任。这些复杂的要求往往会导致营运成本增加和产品上市延迟，尤其是在特殊应用领域。据欧洲医疗技术协会（MedTech Europe）称，到2024年，由于这些资源密集型标准，26.6%的体外诊断设备製造商计划将其孤儿药产品组合中不到5%的产品转移到新的法规结构下。因此，这些监管障碍构成了一项重大挑战，可能会限制创新检测解决方案的普及，并阻碍更广泛的市场成长。

市场驱动因素

全球感染疾病和遗传性疾病负担日益加重，是推动qPCR设备普及应用的主要动力，也因此对精准快速的分子诊断平台的需求日益增长。随着病原体的不断演变和慢性遗传性疾病盛行率的上升，临床检查室高度依赖即时PCR进行高灵敏度的检测和定量，这对于患者照护至关重要。世界卫生组织（世卫组织）于2025年11月更新的《结核病关键事实》预测，2024年全球将有约1,070万人感染结核病，凸显了建立健全诊断基础设施的迫切性。如此沉重的疾病负担要求我们持续采购qPCR系统，以确保及时检测和有效控制疫情，这也巩固了该技术在现代医学中的重要性。

同时，生命科学研究领域公共和私人资金的大幅成长正在推动下一代基因组学技术的进步。产业领导企业正大力投资研发，以提升设备的自动化程度、处理能力和冗余性，从而直接满足市场对更高效率的需求。根据赛默飞世尔科技公司于2025年10月发布的2025年第三季财报，截至2025年9月30日的财年，其研发总支出达到14.1亿美元，展现了公司对创新持续的财务投入。这项投资支撑了市场的活力，主要企业在经济波动的情况下依然保持强劲的盈利表现便印证了这一点。例如，凯杰公司在2025年11月发布的2025年第三季财报中指出，截至2025年9月30日的12个月内，其营收达到20.7亿美元，支撑了市场对分子检测解决方案的持续需求。

市场挑战

全球qPCR仪器市场的发展很大程度上受到体外诊断领域严格监管的限制。这种复杂的合规环境给製造商带来了沉重的营运负担，需要提供大量的技术文件和严谨的临床证据才能获得仪器认证。企业被迫重新分配资金和人员以满足这些高标准，这不可避免地减少了用于研发下一代qPCR平台的资源。因此，先进诊断工具的上市被推迟，製造商也越来越不愿意进入合规成本高或核准流程不确定的市场。

这些监管障碍的具体影响体现在主要产业参与者在市场准入方面的策略选择。根据欧洲医疗技术协会（MedTech Europe）预测，到2024年，选择欧盟作为其首批产品上市主要区域的领先体外诊断试剂製造商比例将比先前的管理体制下下降40%。这一趋势表明，合规方面的困难正在积极阻碍新技术的商业化。这些法规透过减缓产品创新步伐和设置市场准入壁垒，直接限制了新解决方案的可用性，并正在扼杀整个qPCR仪器产业的成长。

市场趋势

製造商正积极研发紧凑型、电池供电的携带式qPCR设备，以方便在急诊、诊所和现场等环境中分散式检查。这种小型化趋势使医疗专业人员能够在临床环境中进行先进的分子诊断，与传统的中心检查室相比，显着缩短了获得检测结果的时间。这些更有效率系统的快速普及体现在市场对专为非检查室环境设计的平台的需求不断增长。根据生物梅里埃公司于2025年9月发布的《2025年上半年财务业绩报告》，SPOTFIRE照护现场系统的有机销售额同比增长143%，凸显了该行业向便捷的、床边检测方案的强劲转变。

同时，在单次反应中识别多个标靶（例如复杂的病原体组合）的需求，正显着推动高通量检测能力的提升。检查室优先选择能够同时分析多个通道的仪器，以节省宝贵的患者检体并提高诊断效率，从而超越基本的单一标靶检测。这种对全面综合征检测的需求，正透过整合更广泛的检测项目和更高的通道数量，改变产品系列。根据QIAGEN于2025年11月发布的2025年第三季财报，QIAstat-Dx综合征检测平台的销售额在不计外汇影响的情况下增长了11%，这表明市场对能够优化工作流程效率的先进多重技术有着强劲的需求。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球qPCR仪器市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依测试类型（7500、QuantStudio Dx、QuantStudio 5、ViiA 7 Dx、One Step/One Step Plus、LightCycler 2.0、Cobas 4800、CFX96、SmartCycler、GeneXpert、Rotor-Gene Q 5Plex HRM System System、Rotor-Gene、BI System、RoIL MAY
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美qPCR仪器市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲qPCR仪器市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区qPCR设备市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲qPCR设备市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲qPCR设备市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球qPCR仪器市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Thermo Fisher Scientific, Inc.
• F. Hoffmann-La Roche Ltd.
• AstraZeneca Inc.
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• QIAGEN NV
• Agilent Technologies, Inc.
• Abbott Laboratories Inc.
• Azure Biosystems Inc.
• Bio Molecular Systems Pty Ltd

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global qPCR Instruments Market is projected to expand from USD 1.29 Billion in 2025 to USD 1.94 Billion by 2031, registering a CAGR of 7.04%. This market consists of sophisticated analytical platforms that integrate thermal cycling with fluorescence detection to amplify and quantify nucleic acids in real-time, serving essential roles in life sciences research and clinical diagnostics. Key factors fueling this growth include the rising global incidence of genetic disorders and infectious diseases, which require high-sensitivity, rapid molecular testing capabilities. Additionally, sustained investment in genomic research and the broader adoption of personalized medicine protocols act as vital pillars supporting the ongoing demand for these precise diagnostic tools, ensuring their relevance beyond temporary technological shifts.

However, the market encounters substantial obstacles due to an increasingly strict regulatory environment for in vitro diagnostics, which imposes heavy compliance responsibilities on device manufacturers. These complex requirements often increase operational costs and postpone product launches, particularly affecting specialized applications. According to MedTech Europe, in 2024, 26.6% of in vitro diagnostic manufacturers intended to transition less than 5% of their orphan device portfolios to the new regulatory framework because of these resource-demanding standards. Consequently, such regulatory barriers pose a significant challenge that threatens to limit the accessibility of innovative testing solutions and impede broader market growth.

Market Driver

The increasing global burden of infectious diseases and genetic disorders acts as a major catalyst for the adoption of qPCR instruments, driving the need for precise and rapid molecular diagnostic platforms. As pathogens evolve and the prevalence of chronic genetic conditions grows, clinical laboratories depend heavily on real-time PCR for sensitive detection and quantification essential to patient care. According to the World Health Organization's 'Tuberculosis Key Facts' update in November 2025, an estimated 10.7 million people contracted tuberculosis globally in 2024, highlighting the urgent requirement for strong diagnostic infrastructure. This significant disease burden ensures the continued procurement of qPCR systems to guarantee timely detection and effective outbreak control, cementing the technology's importance in modern healthcare.

Simultaneously, substantial increases in public and private funding for life sciences research are stimulating the advancement of next-generation genomic technologies. Industry leaders are investing heavily in research and development to improve instrument automation, throughput, and multiplexing capabilities, directly responding to market needs for greater efficiency. According to Thermo Fisher Scientific's 'Third Quarter 2025 Earnings Release' in October 2025, R&D expenses for the year ending September 30, 2025, totaled $1.41 billion, demonstrating a sustained financial dedication to innovation. This investment supports market vitality, as shown by major players maintaining robust revenues despite economic volatility; for instance, QIAGEN reported in its 'Q3 2025 Results' in November 2025 that revenue for the twelve months ending September 30, 2025, reached $2.07 billion, underscoring persistent demand for molecular testing solutions.

Market Challenge

The expansion of the Global qPCR Instruments Market is heavily hindered by stringent regulatory frameworks governing in vitro diagnostics. This complicated compliance landscape places significant operational demands on manufacturers, necessitating extensive technical documentation and rigorous clinical evidence to achieve device certification. As companies are compelled to reallocate capital and staff to meet these elevated standards, resources meant for the research and development of next-generation qPCR platforms are inevitably diminished. As a result, the launch of advanced diagnostic tools is postponed, and manufacturers are increasingly reluctant to enter markets characterized by high compliance costs or uncertain approval timelines.

The tangible effect of these regulatory obstacles is reflected in the strategic choices major industry players make regarding market entry. According to MedTech Europe, in 2024, large in vitro diagnostic manufacturers indicated a 40% decrease in selecting the European Union as their primary region for initial product launches compared to earlier regulatory systems. This pattern illustrates how compliance difficulties actively deter the commercialization of new technologies. By retarding the speed of product innovation and establishing barriers to market access, these regulations directly limit the availability of novel solutions and suppress the overall growth of the qPCR instruments sector.

Market Trends

Manufacturers are actively pursuing the development of compact, battery-powered, and portable qPCR devices to facilitate decentralized testing in emergency departments, clinics, and field settings. This trend toward miniaturization permits healthcare professionals to perform advanced molecular diagnostics at the point of care, thereby drastically shortening turnaround times relative to conventional centralized laboratories. The swift uptake of these streamlined systems is demonstrated by the rising demand for platforms engineered specifically for non-laboratory contexts. According to bioMerieux's 'First-Half 2025 Financial Results' in September 2025, organic sales for the SPOTFIRE point-of-care system rose by 143% over the prior year, emphasizing the sector's strong shift toward accessible, near-patient testing options.

At the same time, there is a marked increase in high-multiplicity multiplexing capabilities, spurred by the essential need to identify multiple targets, such as complex pathogen panels, within a single reaction. Laboratories are favoring instruments capable of analyzing numerous channels simultaneously to conserve precious patient samples and enhance diagnostic efficiency, advancing beyond basic single-target assays. This requirement for comprehensive syndromic testing is transforming product portfolios as companies incorporate broader detection menus and higher channel counts. According to QIAGEN's 'Q3 2025 Results' in November 2025, sales of the QIAstat-Dx syndromic testing platform increased by 11% at constant exchange rates, indicating a robust market preference for advanced multiplexing technologies that optimize workflow productivity.

Key Market Players

• Thermo Fisher Scientific, Inc.
• F. Hoffmann-La Roche Ltd.
• AstraZeneca Inc.
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• QIAGEN N.V.
• Agilent Technologies, Inc.
• Abbott Laboratories Inc.
• Azure Biosystems Inc.
• Bio Molecular Systems Pty Ltd

Report Scope

In this report, the Global qPCR Instruments Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

qPCR Instruments Market, By Test Type

• 7500
• QuantStudio Dx
• QuantStudio 5
• ViiA 7 Dx
• One Step/One
• Step Plus
• LightCycler 2.0
• Cobas 4800
• CFX96
• SmartCycler
• GeneXpert
• Rotor-Gene Q 5Plex HRM System
• Rotor-Gene Q
• BIOFIRE FILMARRAY SYSTEMS
• BMS Mic System

qPCR Instruments Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global qPCR Instruments Market.

Available Customizations:

Global qPCR Instruments Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global qPCR Instruments Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (7500, QuantStudio Dx, QuantStudio 5, ViiA 7 Dx, One Step/One, Step Plus, LightCycler 2.0, Cobas 4800, CFX96, SmartCycler, GeneXpert, Rotor-Gene Q 5Plex HRM System, Rotor-Gene Q, BIOFIRE FILMARRAY SYSTEMS, BMS Mic System)
  • 5.2.2. By Region
  • 5.2.3. By Company (2025)
• 5.3. Market Map

6. North America qPCR Instruments Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States qPCR Instruments Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
  • 6.3.2. Canada qPCR Instruments Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
  • 6.3.3. Mexico qPCR Instruments Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type

7. Europe qPCR Instruments Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany qPCR Instruments Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
  • 7.3.2. France qPCR Instruments Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
  • 7.3.3. United Kingdom qPCR Instruments Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Test Type
  • 7.3.4. Italy qPCR Instruments Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
  • 7.3.5. Spain qPCR Instruments Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type

8. Asia Pacific qPCR Instruments Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China qPCR Instruments Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
  • 8.3.2. India qPCR Instruments Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
  • 8.3.3. Japan qPCR Instruments Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
  • 8.3.4. South Korea qPCR Instruments Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
  • 8.3.5. Australia qPCR Instruments Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type

9. Middle East & Africa qPCR Instruments Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type
  • 9.2.2. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia qPCR Instruments Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
  • 9.3.2. UAE qPCR Instruments Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
  • 9.3.3. South Africa qPCR Instruments Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type

10. South America qPCR Instruments Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type
  • 10.2.2. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil qPCR Instruments Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
  • 10.3.2. Colombia qPCR Instruments Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
  • 10.3.3. Argentina qPCR Instruments Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global qPCR Instruments Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. F. Hoffmann-La Roche Ltd.
• 15.3. AstraZeneca Inc.
• 15.4. Bio-Rad Laboratories, Inc.
• 15.5. Danaher Corporation
• 15.6. QIAGEN N.V.
• 15.7. Agilent Technologies, Inc.
• 15.8. Abbott Laboratories Inc.
• 15.9. Azure Biosystems Inc.
• 15.10. Bio Molecular Systems Pty Ltd

16. Strategic Recommendations

17. About Us & Disclaimer